

## STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W. . WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 . FACSIMILE. (202) 371-2540 . www.skgf.com



ROBERT GREENE STERNE JOHN M. COVERT\* EDWARD J. KESSLER ORGE A. GOLDSTEIN AMUEL L. FOX\*\*\* DAVID K.S. CORNWELL ROBERT W. ESMOND TRACY-GENE G DURKIN MICHELE A. CIMBALA MICHAEL B. RAY ROBERT E. SOKOHL ERIC K. STEFFE MICHAEL Q. LEE STEVEN R. LUDWIG

LINDA E ALCORN ROBERT C MILLONIG MICHAEL V MESSINGER EDWARD W YEE JUDITH U KIM TIMOTHY J. SHEA, JR DONALD R MCPHAIL PATRICK E. GARRETT STEPHEN G. WHITESIDE JEFFREY T. HELVEY\* HEIDI L KRAUS JEFFREY R. KURIN RAYMOND MILLIEN

PATRICK D O'BRIEN LAWRENCE B BUGAISKY CRYSTAL D SAYLES ALBERT L FERRO\* DONALD R BANOWIT PETER A JACKMAN MOLLY A MCCALL TERESA U MEDLER JEFFREY S WEAVER KRISTIN K. VIDOVICH KENDRICK P PATTERSON DONALD J FEATHERSTONE

GRANT E REED VINCENT L CAPUANO JOHN A. HARROUN\* ALBERT J FASULO II\* W. BRIAN EDGE\* ELDORA ELLISON FLOYD\* W RUSSELL SWINDELL THOMAS C FIALA LONNY L. MULLER\* BRIAN J DEL BUONO\* VIRGIL L BEASTON\* RYAN J. STAMPER\*

KAREN R MARKOWICZ\*\* SUZANNE E ZISKA\*\* ANDREA J KAMAGE\*\* NANCY J. LEITH\*\* ELIZABETH J HAANES\*\* MARK P. TERRY\*\*

\*BAR OTHER THAN D C \*\*REGISTERED PATENT AGENT \*\*\*SENIOR COUNSEL

April 10, 2001

WRITER'S DIRECT NUMBER: (202) 371-2560 INTERNET ADDRESS: RESMOND@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

**Box Patent Application** 

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No:

To be assigned (continuation of 09/103,577, filed June 24, 1998,

allowed)

Filed:

April 10, 2001

For:

Method for Isolating and Recovering Target DNA or RNA

Molecules Having a Desired Nucleotide Sequence

Inventors:

P. Nisson et al.

Our Ref:

0942.4800002/RWE/ALS

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- PTO Fee Transmittal (Form PTO/SB/17) (in duplicate); 1.
- PTO Utility Patent Application Transmittal (Form PTO/SB/05); 2.
- U.S. Utility Patent Application entitled: 3.

Method for Isolating and Recovering Target DNA or RNA Molecules Having a Desired Nucelotide Sequence

and naming as inventors:

 Commissioner for Patents April 10, 2001 Page 2

Paul E. NISSON, Joel JESSE, and Wu-bo LI

the application consisting of:

- a A specification containing:
  - i. 46 pages of description prior to the claims (including a sequence listing on pages 42 to 46);
  - ii. 4 pages of claims (40 claims);
  - iii. a one (1) page abstract;
- b  $\underline{3}$  sheets of drawings: (Figures  $\underline{1-3}$ ); and
- c. A copy of the executed combined Declaration and Power of Attorney, as originally filed in parent U.S. Appl. No. 09/103,577;
- 4. Application Data Sheet;
- 5. A Preliminary Amendment;
- 6. Amendment and Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
- 7. 4 pages of a paper copy of a sequence listing;
- 8. A computer readable copy of the sequence listing;
- 9. Letter to PTO Draftsman: Submission of Formal Drawings (in duplicate);
- 10. Three (3) sheets of Formal Drawings (Figs. 1-3);
- 11. Authorization to Treat a Reply As Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate);
- 12. A copy of the Assignment as originally filed in parent U.S. App. No. 09/103,577;
- 13. A copy of the executed Power of Attorney from Assignee as originally filed in parent U.S. Appl. No.09/103,577;

Commissioner for Patents April 10, 2001 Page 3

- 14. A copy of the certificate under 37 C.F.R. § 3.73(b) as originally filed in parent U.S. Appl. No.09/103,577;
- 15. Revocation of Prior Power of Attorney and Appointment of New Attorneys of Record, as originally filed in parent U.S. Appl. No. 09/103,577;
- 16. A copy of the merger document between Life Technologies, Inc. and Invitrogen Corporation, recorded against parent U.S. Appl. No. 09/103,577 at Reel 011452, Frame 0123;
- 17. Two (2) return postcards; and
- 18. Our check No. 30909 for \$ 1,610.00 to cover: \$ 710.00 Filing fee for patent application; and \$ 900.00 Fee for excess claims.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants

SobutW. Somme

Registration No. 32,893

RWE/ALS/asl Enclosures Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

\$ 1,610.00

Comp	lete if Known			
Application Number	To be assigned (Cont. of 09/103,577, filed June 24, 1998, allowed)			
Filing Date	April 10, 2001			
First Named Inventor	Paul E. NISSON			
Examiner Name	To be assigned			
Group Art Unit	To be assigned			
Attorney Docket No.	0942.4800002/RWE/ALS			

METH	METHOD OF PAYMENT (check one) FEE CALCULATION (continued)									
1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:				TIONAL Entity		Entity				
Deposit Account Number	19-0036		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Do	escription	Fee paid	
Deposit Account Name	Sterne, Kessler, Go	oldstein & Fox P.L L.C	105	130	205	65	Surcharge - late filing for	ee or oath		
Charge Any Additional Fee Required Under 37 CFR §§ 1 16 and 1.17		127	50	227	25	Surcharge - late provisional	filing fee or cover she	et		
		139	130	139	130	Non-English specific				
Applicant claims small entity status See 37 CFR 1.27			147	2,520	147	2,520	For filing a request for	ex parte reexamii	nation	
See 37 CFR 1.27				920*	112	920*	Requesting publication o	er		
2. ⊠päyment Enclosed:				1,840*	113	1,840*	Requesting publication of SIR after Examiner action			
*Charge any deficiencie calculations of Parts 1,	115	110	215	55	Extension for reply within first month					
11.5 11.5 11.5 11.5 11.5 11.5 11.5 11.5	FEE CALCULA	ATION	116	390	216	195	Extension for reply wi	thin second month		
1. BASIC FILING	EE		117	890	217	445	Extension for reply wi	thin third month		
Large Entity Sma			118	1,390	218	695	Extension for reply wi	thin fourth month		
	Fee Fee Desd le (\$)	cription Fee Paid	128	1,890	228	945	Extension for reply wi	thin fifth month		
101 1 710 201	355 Utility film	ng fee \$710.00	119	310	219	155	Notice of Appeal			
106 📑 320 206	160 Design fil	ling fee	120	310	220	155	Filing a brief in support of an appeal			
107 490 207	245 Plant filin	ng fee	121	270	221	135	Request for oral hearing			
108 =710 208	355 Reissue t	filing fee	. 138	1,510	138	1,510	Petition to institute a public use proceeding			
114 150 214	75 Provision	al filing fee	140	110	240	55	Petition to revive - unavoidable			
			141	1,240	241	620	Petition to revive - unintentional			
SUBTOTAL	. <b>(1)</b> (\$) <u>710.00</u>		- 142	1,240	242	620	Utility issue fee (or reissue)			
			143	440	243	220	Design Issue fee			
			144	600	244	300	Plant issue fee			
			122	130	122	130	Petitions to the Comm	nissioner		
2. EXTRA CLAIM I	FEES Extra	Fee from below Fee Paid	123	130	123	130	Petitions related to provisional applications			
Total Claims _70_		K <u>18.00</u> = \$900.00	126	180	126	180	Submission of Information Disclosure Stmt			
Indep. Claims 3	<del></del>	<u> </u>	581	40	481	40	Recording each patent assignment per property (times number of properties)			
Multiple Dependent	<u></u>	<u> </u>	146	710	246	355	Filing a submission after final rejection (37 CFR 1.129(a))			
Large Entity Smal	Fee Fee D	escription	149	710	249	355	For each additional invention to be examined (37 CFR 1.129(b))			
Code (\$) Code 103 18 203		excess of 20	179	710	279	355	Request for Continue	d Examination (RC	(E)	
102 <sub>,</sub> 80 202 104 270 204	•	nt claims in excess of 3	169	900	169	900	Request for expedited examination of a design application			
108 80 209	40 **Reissue i	independent claims over original	Other fee	(specify):			••		<del></del>	
110 18 210	patent	claims in excess of 20 and over	Other fee (specify) .							
SU	*Reduced	by Basic F	iling Fee	Paid			<u> </u>			
** or number previously	paid, if greater, For R	Reissues, see above	1			···	SUBTOTAL (			
SUBMITTED BY					Complete (if ap	plicable)				
Name (Print/Type) Robert W. Esmond				Registration No. (Attorney/Agent)			32,893	Telephone	202-371-2600	
Signature Kobulw. Smood								Date	April 10, 2001	

## Certificate Under 37 C.F.R. § 3.73(b)

Applicant(s): Paul E. Nisson, Joel Jesse and Wu-bo Li
Application No: To Be Assigned Filed: Herewith
For: Method for Isolating and Recovering Target DNA or RNA Molecules having a Desired Nucleotide Sequence,
Life Technologies, Inc., a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership university, government agency, etc.)
states that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:
A. [] An Assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
A chain of title from the inventor(s) of the patent application identified above to the current assignee as shown below:  1. From:
1. From: To:
2. From:To:
The document was recorded in the Patent and Trademark Office at  Reel, or for which a copy thereof is attached.  3. From: To:  The document was recorded in the Patent and Trademark Office at
3. From: To:
and I thought the I though the I thought the I thought the I though
Reel, Frame, or for which a copy thereof is attached.
[ ] Additional documents in the chain of title are listed on a supplemental sheet.
[x] Copies of assignments or other documents in the chain of title are attached.
To the best of the undersigned's knowledge and belief, title of the patent application identified above is in the assignee identified above.
The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.